Hybio Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hybio Pharmaceutical (300199.CS)

Q3 20267 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

August 20267 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

Latest7 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.